MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
DNA 甲基化酶抑制剂激活基因的机制
基本信息
- 批准号:2827904
- 负责人:
- 金额:$ 22.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-12-22 至 2001-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
5-Aza-2'-deoxycytidine (DAC) is an investigational agent with
demonstrated activity in the treatment of acute myeloid leukemia and
likely therapeutic utility in other leukemias and myelodysplastic
syndromes. After incorporation into DNA, DAC inhibits the enzyme DNA
(cytosine-5)-methyltransferase (MT'ase). This inhibition has generally
been assumed to be responsible for its activity. While this action may
be necessary, our preliminary results suggest that MT'ase inhibition
alone does not fully explain DAC's molecular biological effects. In
neoplastic cells in culture, DAC has been shown to decrease the
methylation of 5' regulatory regions and to increase the expression of
tumor suppressor genes silenced by methylation. As a result, it could
inhibit carcinogenesis or tumor progression. DAC has been shown to
reduce polyp formation in a murine model for colonic
preneoplasia when only one copy of the MT'ase gene is present. 5-
Fluoro-2'-deoxycytidine (FdCyd) is another analog which, when present
in DNA, binds irreversibly to MT'ase in vitro. Despite the fact that
both analogs are irreversible inhibitors of the MT'ase, we have obtained
preliminary evidence that FdCyd incorporated into cellular DNA does not
decrease the methylation of the tumor suppressor gene p16. DAC and
FdCyd do differ significantly in their chemical stability; DAC is far
less stable because of its triazine ring structure. Our, Hypothesis is
that, in addition in inhibiting MT'ase, unstable DAC residues in DNA
contribute to the loss of methylation through DNA damage-induced
excision and repair. Our Specific Aims to test this hypothesis are: (1)
to compare the reactivation of p16 by DAC and FdCyd as measured by the
methylation of p16 exon and the expression of p16 mRNA, (2) to compare
the incorporation of DAC and FdCyd into DNA in cells, and (3) to compare
the inhibition of MT'ase by DAC and FdCyd in cells as measured by the
MT'ase activity in cellular extracts and the methylation of newly-
incorporated deoxycytidine residues in DNA. As part of specific aim 3,
we will develop a new assay for MT'ase which does not require measuring
the incorporation of radioactivity from [CH3-3H]-S-adenosylmethionine
into DNA. This new assay will expedite the analysis of samples in this
project and other studies, including future clinical trials. If our
hypothesis is correct, DNA-damaging agents combined with FdCyd should
produce the same effects as DAC does through its two different actions,
MT'ase inhibition and DNA damage. Increasing DNA damage with another
agent might also potentiate the effects of DAC. Thus, our final
specific aim in this project (4) is to determine the effects of DNA-
damaging agents combined with FdCyd and DAC on the methylation and
expression of specific genes. The overall goal of this proposal is to
understand the actions of MT'ase inhibitors and to use this
understanding to develop more effective methods of modulating DNA
methylation in human diseases.
5-氮杂-2‘-脱氧胞苷(DAC)是一种具有
显示出治疗急性髓系白血病的活性和
对其他白血病和骨髓增生异常的可能治疗作用
综合症。在掺入DNA后,DAC抑制了DNA酶
(胞嘧啶-5)甲基转移酶(MT‘酶)。这种抑制通常会
被认为对其活动负责。虽然此操作可能
有必要,我们的初步结果表明,MT‘ase抑制
单靠这一点并不能完全解释DAC的分子生物学效应。在……里面
在培养的肿瘤细胞中,DAC已被证明可减少
5‘调控区的甲基化并增加其表达
肿瘤抑制基因因甲基化而沉默。因此,它可能会
抑制癌变或肿瘤进展。DAC已被证明是
减少小鼠结肠息肉形成的实验研究
只有一份MT‘ase基因存在时的创业症。5
氟-2‘-脱氧胞苷(FdCyd)是另一种类似物,当存在时
在DNA中,在体外不可逆地与MT‘酶结合。尽管事实是
这两个类似物都是MT‘酶的不可逆转的抑制剂,我们已经获得
初步证据表明,掺入细胞DNA的FdCyd不会
减少肿瘤抑制基因p16的甲基化。DAC和
FdCyd在化学稳定性方面确实有很大差异;DAC远远不同
由于其三嗪环结构,稳定性较差。我们的假设是
除了抑制MT‘酶,DNA中不稳定的DAC残基
通过DNA损伤导致甲基化缺失
切除和修复。我们检验这一假说的具体目标是:(1)
为了比较DAC和FdCyd对p16的重新激活,
P16外显子甲基化与p16基因表达的比较
DAC和FdCyd在细胞DNA中的掺入;(3)比较
DAC和FdCyd对细胞MT‘酶的抑制作用
细胞抽提物中MT‘酶活性及新陈代谢产物的甲基化
在DNA中加入了脱氧胞苷残基。作为特定目标3的一部分,
我们将开发一种新的不需要测量的MT‘ase检测方法
[CH_3-~3H]-S-腺苷蛋氨酸的放射性掺入
变成DNA。这种新的化验方法将加快对这一地区样品的分析。
项目和其他研究,包括未来的临床试验。如果我们的
假设是正确的,DNA损伤剂与FdCyd联合应该
通过两个不同的动作产生与DAC相同的效果,
线粒体酶抑制和DNA损伤。与其他人一起增加DNA损伤
药剂也可能增强DAC的作用。因此,我们的决赛
这个项目(4)的具体目标是确定DNA-
FdCyd和DAC联合使用对肿瘤细胞甲基化的影响
特定基因的表达。这项提案的总体目标是
了解MT‘ase抑制剂的作用并使用此
对开发更有效的DNA调控方法的理解
人类疾病中的甲基化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EDWARD M NEWMAN其他文献
EDWARD M NEWMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EDWARD M NEWMAN', 18)}}的其他基金
Phase I Molecular and Clincal Pharmacodynamic Trials
I 期分子和临床药效试验
- 批准号:
7908337 - 财政年份:2009
- 资助金额:
$ 22.6万 - 项目类别:
MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
DNA 甲基化酶抑制剂激活基因的机制
- 批准号:
6124688 - 财政年份:1998
- 资助金额:
$ 22.6万 - 项目类别:
MECHANISM OF GENE ACTIVATION BY DNA METHYLASE INHIBITORS
DNA 甲基化酶抑制剂激活基因的机制
- 批准号:
6329082 - 财政年份:1998
- 资助金额:
$ 22.6万 - 项目类别:
相似海外基金
Deciphering plant stress memory: the exploration of how DNA methylation and the rhizosphere microbiome control stress memory in plants
解读植物逆境记忆:探索DNA甲基化和根际微生物如何控制植物逆境记忆
- 批准号:
BB/Z514810/1 - 财政年份:2024
- 资助金额:
$ 22.6万 - 项目类别:
Fellowship
Next-generation epigenetic analysis: direct reading of DNA methylation
下一代表观遗传分析:直接读取 DNA 甲基化
- 批准号:
DP220102086 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Discovery Projects
stablishment of non-invasive DNA methylation panel for peritoneal metastasis of gastric cancer patients
胃癌腹膜转移非侵入性DNA甲基化检测试剂盒的建立
- 批准号:
23K08210 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decoding AMPK-dependent regulation of DNA methylation in lung cancer
解码肺癌中 DNA 甲基化的 AMPK 依赖性调节
- 批准号:
10537799 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
DNA-methylation to improve conservation of TSD species
DNA 甲基化可改善 TSD 物种的保护
- 批准号:
NE/X012077/1 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Research Grant
Modular workflow for the community-led development of custom livestock DNA methylation arrays
用于社区主导的定制牲畜 DNA 甲基化阵列开发的模块化工作流程
- 批准号:
BB/W019051/1 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Research Grant
DNA methylation and effectors associated with lifestyle diseases study
DNA甲基化和与生活方式疾病相关的效应物研究
- 批准号:
23K16331 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of Molecular Mechanisms of Child Abuse Stress Focusing on DNA Methylation and Development and Application of Quantitative Methods
以DNA甲基化为重点的儿童虐待应激分子机制阐明及定量方法的发展与应用
- 批准号:
23K16378 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Understanding the full spectrum of epigenetic vulnerability in cancer through the delineation of DNA methylation function in gene 3' end
通过描绘基因 3 端 DNA 甲基化功能,全面了解癌症的表观遗传脆弱性
- 批准号:
10765365 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别:
DNA methylation signatures of Alzheimer's disease in aged astrocytes
老年星形胶质细胞中阿尔茨海默病的 DNA 甲基化特征
- 批准号:
10807864 - 财政年份:2023
- 资助金额:
$ 22.6万 - 项目类别: